TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34886910

Group type: EXPERIMENTAL
Intervention: Home therapy group (HT group) directed by surgeons at post-operative appointments
Number of subjects: 200

Group type: COMPARATOR
Intervention: Outpatient rehabilitation by physical therapists (PT group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (PT and HT)
Number of subjects: 200
Study: 34886909

Group type: EXPERIMENTAL
Intervention: Remote nutrition monitoring intervention with tailored nutritional counseling before and after surgery at 2 and 4 weeks after hospital discharge. Participants recorded nutritional intake daily for 30 days, reviewed by registered dietitians.
Number of subjects: 19
Study: 34887051

Group type: COMPARATOR
Intervention: Any PTX device
Number of subjects: 2456

Group type: COMPARATOR
Intervention: PTX drug-coated balloon angioplasty
Number of subjects: 2456

Group type: COMPARATOR
Intervention: PTX drug-eluting stent therapy
Number of subjects: 2456
Study: 34887055

Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography Guided Implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34887348

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced CT (DCE-CT)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Positron emission tomography/CT (PET/CT)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Combined DCE-CT and PET/CT
Number of subjects: 380

Group type: COMPARATOR
Intervention: Cost-effectiveness analysis
Number of subjects: 380
Study: 34887574

Group type: EXPERIMENTAL
Intervention: Immune-modulatory vaccine (IO102/IO103) combined with nivolumab
Number of subjects: 30
Study: 34887772

Group type: EXPERIMENTAL
Intervention: Evolocumab added to moderate-intensity statin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-intensity statin therapy
Number of subjects: 0
Study: 34888043

Group type: EXPERIMENTAL
Intervention: Combined Surgical and Injection of alcohol Treatment (COSIT), mean alcohol volume 72.0 mls, mean follow-up duration 16 months.
Number of subjects: 21
Study: 34888099

Group type: EXPERIMENTAL
Intervention: Short sleep duration (≤6 hours)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Normal sleep duration (>6 hours)
Number of subjects: 429
Study: 34888270

Group type: EXPERIMENTAL
Intervention: Exposure to online games in preschool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not exposed to online games)
Number of subjects: 0
Study: 34888330

Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood gases
Number of subjects: 0
Study: 34888394

Group type: EXPERIMENTAL
Intervention: Serological testing for SARS-CoV-2 antibodies
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Geographic region analysis
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Odds ratio analysis for seropositivity
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Measurement of serum neutralization titers
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Assessment of antibody effectiveness against variants
Number of subjects: 978
Study: 34888436

Group type: EXPERIMENTAL
Intervention: Nail ultrasound (US) imaging
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DIP ultrasound (US) imaging
Number of subjects: 46
Study: 34888518

Group type: EXPERIMENTAL
Intervention: 500 U/1 mL dilution of AbobotulinumtoxinA
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: 500 U/2 mL dilution of AbobotulinumtoxinA
Number of subjects: 321
Study: 34888735

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Fine particulate matter (<2.5 µm) exposure
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Coarse particulate matter (<10 µm) exposure
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 1292
Study: 34889102

Group type: EXPERIMENTAL
Intervention: In-hospital ACEi/ARB use
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Control (no ACEi/ARB use)
Number of subjects: 1686
Study: 34889108

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation in patients with atrial fibrillation and heart failure
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Cryoballoon ablation in patients without heart failure
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation in patients with heart failure
Number of subjects: 1303
Study: 34889115

Group type: EXPERIMENTAL
Intervention: Early presenting patients (<6 hours)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Late presenting patients (6-24 hours)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118
Study: 34889232

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (200 mg/day and 400 mg/day) and pembrolizumab (200 mg every 3 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate and pembrolizumab
Number of subjects: 22
Study: 34889270

Group type: EXPERIMENTAL
Intervention: Behavioral interventions to reduce PM exposure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 34889382

Group type: EXPERIMENTAL
Intervention: Management strategies for priapism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management strategies for chronic leg ulcer disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management strategies for pulmonary hypertension
Number of subjects: 0
Study: 34889384

Group type: EXPERIMENTAL
Intervention: Genetically modified T cells
Number of subjects: 0
Study: 34889407

Group type: EXPERIMENTAL
Intervention: Novel therapies for acute myeloid leukemia (AML)
Number of subjects: 0
Study: 34889746

Group type: EXPERIMENTAL
Intervention: CBT-i Coach app alone
Number of subjects: 33

Group type: COMPARATOR
Intervention: CBT-i Coach app with adjunctive physical activity (PA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (CBT-i Coach app alone and with PA)
Number of subjects: 33
Study: 34889766

Group type: EXPERIMENTAL
Intervention: CONCERN Clinical Decision Support (CDS) system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CONCERN CDS system
Number of subjects: 0
Study: 34889776

Group type: EXPERIMENTAL
Intervention: Combined clinical audits and low-dose, high-frequency (LDHF) in-service training for 6 months
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Refresher course in maternal neonatal and child health (MNCH) for 10 days plus LDHF training for 6 months
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard MNCH refresher training delivered in a classroom setting
Number of subjects: 600
Study: 34889775

Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive intervention group (Fitbit use, daily HRQOL reports, personalized push notifications for 3 months)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (Fitbit use, daily HRQOL reports for 3 months without personalized feedback)
Number of subjects: 3
Study: 34889804

Group type: EXPERIMENTAL
Intervention: General anesthesia consisting of propofol induction and sevoflurane maintenance
Number of subjects: 71
Study: 34890832

Group type: EXPERIMENTAL
Intervention: Ceritinib (≥ 300 mg)
Number of subjects: 285
Study: 34891077

Group type: EXPERIMENTAL
Intervention: mfERG
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: OPs
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls (C)
Number of subjects: 29
Study: 34891223

Group type: EXPERIMENTAL
Intervention: Betibeglogene autotemcel (beti-cel) gene therapy
Number of subjects: 23
Study: 34893017

Group type: EXPERIMENTAL
Intervention: Youth-rated alliance
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Therapist-rated alliance
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Parent-rated alliance
Number of subjects: 65
Study: 34893042

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 134

Group type: COMPARATOR
Intervention: No suction drainage
Number of subjects: 134
Study: 34893522

Group type: EXPERIMENTAL
Intervention: Extracorporeal CO₂ removal (ECCO₂R); mean time on ECCO₂R was 5.4 days.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (Invasive mechanical ventilation - IMV); mean time on IMV was 27 days.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ECCO₂R; 4 patients required IMV, 3 after ECCO₂R weaning.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ECCO₂R; mean ICU stay was 18 days.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (IMV); mean ICU stay was 30 days.
Number of subjects: 51
Study: 34893524

Group type: EXPERIMENTAL
Intervention: Intravenous enadenotucirev plus paclitaxel
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intraperitoneal enadenotucirev monotherapy
Number of subjects: 38
Study: 34893603

Group type: EXPERIMENTAL
Intervention: CAR19 T-cells
Number of subjects: 54
Study: 34893771

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel BCMA-targeted CAR-T cell therapy
Number of subjects: 1
Study: 34893775

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 700

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 700
Study: 34893942

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (150 µg/kg every 3 weeks for 2 cycles; 75 µg/kg Q3W thereafter)
Number of subjects: 328
Study: 34893945

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 14
Study: 34893952

Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All procedures and treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study: 34894221

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (3 priming doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (annual booster dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (2nd booster dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (post-vaccination antibody response)
Number of subjects: 0
Study: 34894235

Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (CoronaVac), two doses administered at D0 and D28.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MMF monotherapy in SSc patients.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (153 individuals without SSc).
Number of subjects: 51
Study: 34894307

Group type: EXPERIMENTAL
Intervention: adjunctive brexpiprazole 1-3 mg/day
Number of subjects: 105
Study: 34894329

Group type: EXPERIMENTAL
Intervention: iGlarLixi with SGLT2i
Number of subjects: 1631

Group type: COMPARATOR
Intervention: iGlarLixi without SGLT2i
Number of subjects: 1631
Study: 34894328

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (22 subjects)
Number of subjects: 36
Study: 34894378

Group type: EXPERIMENTAL
Intervention: LevelMind@JC service
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Generic youth services
Number of subjects: 1300
Study: 34894681

Group type: EXPERIMENTAL
Intervention: JNK inhibitors with increased JNK1 bias, specifically a novel series of 2,4-dialkylamino-pyrimidine-5-carboxamides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral dosing of optimized JNK inhibitors
Number of subjects: 0
Study: 34895133

Group type: EXPERIMENTAL
Intervention: CGRP antibodies treatment for 3 months
Number of subjects: 22
Study: 34895181

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg over 12 weeks
Number of subjects: 122
Study: 34895190

Group type: EXPERIMENTAL
Intervention: Conservative treatment or Open Reduction Internal Fixation (ORIF)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 55
Study: 34895196

Group type: EXPERIMENTAL
Intervention: Intervention (CIrCLE of Life Initiative)
Number of subjects: 537
Study: 34895259

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stromal cells (10, 40, and 100 million cells per knee)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single injection of autologous cells
Number of subjects: 0
Study: 34895264

Group type: EXPERIMENTAL
Intervention: Standard ovarian stimulation regimen of 150 micrograms corifollitropin alfa (Elonva®) followed by 200 IU follitropin beta (Puregon®) per day
Number of subjects: 192
Study: 34895272

Group type: EXPERIMENTAL
Intervention: HIV vaccine and monoclonal antibody trials
Number of subjects: 1934

Group type: EXPERIMENTAL
Intervention: Current recruitment approach
Number of subjects: 1934

Group type: EXPERIMENTAL
Intervention: Current trials
Number of subjects: 1934
Study: 34895290

Group type: EXPERIMENTAL
Intervention: IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin (30 mg/kg/d) + prednisolone (2 mg/kg/d with a maximum dose of 60 mg tapered over 15 days after normalization of C-reactive protein concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin (30 mg/kg/d)
Number of subjects: 0
Study: 34895296

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 0
Study: 34895314

Group type: EXPERIMENTAL
Intervention: Incremental vestibular adaptation training device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional vestibular rehabilitation
Number of subjects: 0
Study: 34895320

Group type: EXPERIMENTAL
Intervention: CT angiography (CTA)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Non-CTA
Number of subjects: 382
Study: 34895316

Group type: EXPERIMENTAL
Intervention: Multi-modal assessment of sarcopenia and its underlying mechanisms in chronic inflammatory diseases.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Healthy individuals (control group) for comparison.
Number of subjects: 220
Study: 34895347

Group type: EXPERIMENTAL
Intervention: Leader-perceived Implementation Citizenship Behavior (ICB)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Subscale of keeping informed
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Practitioner-perceived implementation leadership
Number of subjects: 194
Study: 34895351

Group type: EXPERIMENTAL
Intervention: Nutrition knowledge index (NKI) scores for females
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nutrition knowledge index (NKI) scores for males
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Self-reported ability to seek and verify nutrition information
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Factors associated with higher NKI scores
Number of subjects: 400
Study: 34895430

Group type: EXPERIMENTAL
Intervention: Clogs
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Sneakers
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Sandals
Number of subjects: 153

Group type: COMPARATOR
Intervention: Specialty preference
Number of subjects: 153

Group type: COMPARATOR
Intervention: Seniority preference
Number of subjects: 153

Group type: COMPARATOR
Intervention: Footwear condition
Number of subjects: 153

Group type: COMPARATOR
Intervention: Gender preference
Number of subjects: 153
Study: 34895487

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Number of subjects: 148
Study: 34895750

Group type: EXPERIMENTAL
Intervention: Oral Anticoagulants (OACs)
Number of subjects: 9135

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 9135

Group type: EXPERIMENTAL
Intervention: Vitamin-K-Antagonists (VKAs)
Number of subjects: 9135
Study: 34895798

Group type: EXPERIMENTAL
Intervention: Motivational messages sent via SMS for 21 days (n=41)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (n=46)
Number of subjects: 87
Study: 34895804

Group type: EXPERIMENTAL
Intervention: Females with T2D
Number of subjects: 3163

Group type: COMPARATOR
Intervention: Males with T2D
Number of subjects: 3163
Study: 34895986

Group type: EXPERIMENTAL
Intervention: Tumor-associated neodifferentiation (TAND) concept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer-associated fibroblasts (CAFs)
Number of subjects: 0
Study: 34896005

Group type: EXPERIMENTAL
Intervention: Single-stage two-layer continuous closure
Number of subjects: 11
Study: 34896295

Group type: EXPERIMENTAL
Intervention: Notification of clinicians about patient overdose via a letter.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 34896356

Group type: EXPERIMENTAL
Intervention: Interdisciplinary telemedicine (IDC-TM)
Number of subjects: 124

Group type: COMPARATOR
Intervention: In-person clinical care
Number of subjects: 124
Study: 34896459

Group type: EXPERIMENTAL
Intervention: Lattice SBRT delivering 20 Gy in 5 fractions with a simultaneous integrated boost (SIB) of 66.7 Gy.
Number of subjects: 20
Study: 34896641

Group type: EXPERIMENTAL
Intervention: Direct access to publicly subsidized physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard referral to physiotherapy)
Number of subjects: 0
Study: 34896646

Group type: EXPERIMENTAL
Intervention: Diode Laser fiber type-selective stimulator (DLss)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional quantitative sensory testing (QST)
Number of subjects: 20
Study: 34897194

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34897375

Group type: EXPERIMENTAL
Intervention: FATIGUE-PRO instrument (31 items across three scales: physical fatigue, mental and cognitive fatigue, susceptibility to fatigue)
Number of subjects: 106
Study: 34897582

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg qw
Number of subjects: 391
Study: 34898139

Group type: EXPERIMENTAL
Intervention: LentiGlobin infusion
Number of subjects: 35
Study: 34898239

Group type: EXPERIMENTAL
Intervention: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (Dara-KRd)
Number of subjects: 123
Study: 34898392

Group type: EXPERIMENTAL
Intervention: Prolonged continuous monitoring of regional lung function
Number of subjects: 0
Study: 34898461

Group type: EXPERIMENTAL
Intervention: DART assessment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Physiotherapist-led triage
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: DART user satisfaction
Number of subjects: 76
Study: 34898655

Group type: EXPERIMENTAL
Intervention: Personalised pacemaker reprogramming
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 34899170

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular Vagus Nerve Stimulation (taVNS) during robotic training (9 sessions, 1 hour each, 3 times a week for 3 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Robotic training without taVNS (control group)
Number of subjects: 36
Study: 34899612

Group type: EXPERIMENTAL
Intervention: 0.20 mg/kg biweekly PEG-rhGH
Number of subjects: 585

Group type: COMPARATOR
Intervention: 0.20 mg/kg once-weekly PEG-rhGH
Number of subjects: 585

Group type: COMPARATOR
Intervention: 0.25 mg/kg daily rhGH
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Long-acting PEG-rhGH
Number of subjects: 585
Study: 34900237

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34900661

Group type: EXPERIMENTAL
Intervention: Gross Tissue Response (GTR) system
Number of subjects: 102
Study: 34900737

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34900741

Group type: EXPERIMENTAL
Intervention: surgery + Cs-131
Number of subjects: 49
Study: 34901095

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34901100

Group type: EXPERIMENTAL
Intervention: Botanical product containing cistanche and ginkgo extracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34901129

Group type: EXPERIMENTAL
Intervention: Beans-vegetables dietary pattern
Number of subjects: 3334

Group type: EXPERIMENTAL
Intervention: Fish-meat-eggs dietary pattern
Number of subjects: 3334

Group type: EXPERIMENTAL
Intervention: Nuts-whole grains dietary pattern
Number of subjects: 3334

Group type: EXPERIMENTAL
Intervention: Organ-poultry-seafood dietary pattern
Number of subjects: 3334

Group type: EXPERIMENTAL
Intervention: Rice-wheat-fruits dietary pattern
Number of subjects: 3334
Study: 34901220

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34901464

Group type: COMPARATOR
Intervention: Topical 0.5% moxifloxacin plus topical placebo plus sham CXL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical 0.5% moxifloxacin plus difluprednate 0.05% plus sham CXL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical 0.5% moxifloxacin plus difluprednate 0.05% plus CXL
Number of subjects: 0
Study: 34901693

Group type: EXPERIMENTAL
Intervention: Age-based anthropometric cutoffs for adolescent girls (10 to <19 y)
Number of subjects: 0
Study: 34901797

Group type: EXPERIMENTAL
Intervention: Ixazomib 4mg weekly for 24 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ixazomib treatment
Number of subjects: 16
Study: 34901863

Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34901885

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (3 μg in 0.5 mL, intramuscular injection) administered on day 0 and day 28
Number of subjects: 942

Group type: COMPARATOR
Intervention: Control group (seropositive controls and seronegative controls)
Number of subjects: 942
Study: 34901915

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy (AIT)
Number of subjects: 46024

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 46024
Study: 34901926

Group type: EXPERIMENTAL
Intervention: Digital health coaching intervention for T2DM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34902012

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0